Hennion & Walsh Asset Management, Inc. Iovance Biotherapeutics, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.15 Billion
- Q1 2025
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 366,775 shares of IOVA stock, worth $748,221. This represents 0.06% of its overall portfolio holdings.
Number of Shares
366,775
Previous 335,981
9.17%
Holding current value
$748,221
Previous $2.49 Million
47.51%
% of portfolio
0.06%
Previous 0.12%
Shares
14 transactions
Others Institutions Holding IOVA
# of Institutions
334Shares Held
247MCall Options Held
1.34MPut Options Held
1.61M-
Vanguard Group Inc Valley Forge, PA27.8MShares$56.7 Million0.0% of portfolio
-
Mhr Fund Management LLC New York, NY24.4MShares$49.8 Million12.15% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$43.3 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY12.7MShares$25.9 Million1.77% of portfolio
-
State Street Corp Boston, MA11MShares$22.5 Million0.0% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $322M
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...